NorthStar Medical Radioisotopes awarded three patents for Mo-99 production process

Michael Walter | June 10, 2016 | Radiology Business | Medical Imaging

NorthStar Medical Radioisotopes, a nuclear medicine company based out of Madison, Wis., announced this week it has been awarded three patents related to its processes for producing molybdenum-99 (Mo-99) without using highly enriched uranium.

The patents were for the company’s RadioGenix isotope separation system and two related components: the Mo-99 Source Vessel and the Technetium-99m (Tc-99m) Product Cartridge.

The RadioGenix system allows users to process different medical isotopes. The Mo-99 Source Vessel will be used in shipping Mo-99 to customers, and the Tc-99m product cartridge filters out the remaining Mo-99 from the Tc-99m and “provides cold sterilization of the final eluent.”

The company was also awarded a trademark approval for NuMolium, its brand of Mo-99.

Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Imaging

American College of Radiology announces significant expansion of Lung Cancer Screening Registry

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

Health Imaging

AI reduces CT lung cancer screening workload by nearly 80%

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

Health Imaging

Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

NorthStar Medical Radioisotopes awarded three patents for Mo-99 production process

Related Content

Around the web